GIANT BIOGENE (HKEX: 02367) has released its 2025 Environmental, Social and Governance (ESG) Report, detailing broad-based improvements in governance, product quality, environmental stewardship and human-capital management for the year ended 31 December 2025.
Governance and Compliance • A three-tier ESG structure led by the board, a Corporate Governance Committee and functional departments is now fully operational. • Roughly 1,800 quality-system documents were added or revised; six internal quality reviews were completed across cosmetics, medical device and food segments. • Anti-corruption coverage reached 100% of directors, employees and suppliers through more than 2,000 training sessions; no corruption or bribery cases were recorded.
Product Quality and Innovation • First-inspection pass rate held at ≥ 98.5% and customer satisfaction at ≥ 95%. • R&D spend totalled RMB 88.79 million, equal to 1.60% of revenue. • Regulatory assets include 140+ cosmetic filings, 30+ Class II and two Class III medical-device registrations; R&D pipeline exceeds 140 ongoing projects. • IP portfolio expanded to 209 granted or pending patents and 833 trademarks; recombinant collagen molecule library reached 50 variants.
Environmental Performance • Certified to ISO 14001, ISO 45001, ISO 50001 and awarded “National Green Factory” status. • Scope 1 emissions: 4,272.29 tCO₂e; Scope 2 emissions: 15,527.49 tCO₂e; total 19,799.78 tCO₂e, or 3.59 tCO₂e per RMB 1 million revenue. • Energy use: 5,518.35 tce, of which 3,346.18 tce were direct and 2,172.17 tce indirect; rooftop solar generated 136,983.78 kWh. • Water consumption: 462,622.80 m³ (83.83 m³ per RMB 1 million revenue); wastewater discharge 36,356.95 t with 100% compliance. • Hazardous waste: 65.18 t (0.012 t per RMB 1 million revenue); non-hazardous waste: 366.72 t (0.066 t per RMB 1 million revenue); no environmental violations or penalties.
Human Capital • Total headcount reached 2,201 (41% male, 59% female). • Workforce received 102,480 training hours; 100% completion rate for safety programmes. • Zero fatalities; 414 lost workdays due to injury. • Employee turnover stood at 32.3%; tailored retention initiatives include broadband pay bands, OKR-based performance reviews and internal promotion pathways.
Community Engagement • Charitable contributions exceeded RMB 4.00 million, covering education, healthcare and environmental initiatives. • Key campaigns included a four-month donation drive benefiting frontline workers, a recycling programme converting 2,576,430 used packages into school supplies, and nationwide skin-health education across 400+ hospitals.
Industry Leadership • Co-authored the industry standard “Recombinant Collagen Dressing” and led the group standard “Recombinant Type IV Collagen for Cosmetics,” reinforcing regulatory benchmarks for emerging bioactive ingredients. • Participated in more than 100 professional forums, including CSD 2025, CDA 2025 and CBA 2025, to disseminate advances in recombinant collagen applications.
GIANT BIOGENE concludes that systematic ESG integration, sustained R&D investment and rigorous compliance underpin its strategy to drive technology-based beauty and health solutions while advancing environmental and social value.
Comments